Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
52 stopped studies mapped to Extrapulmonary Neuroendocrine Carcinoma and descendants · 85% state a reason
Over the 52 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05058651 | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy… | Phase 2 / Phase 3 | suspended | Sep 28, 2021 | National Cancer Institute (NCI) | End of Initial Phase of Multi-phase protocol | Other (stated, no rule matched) |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate… | Phase 1 / Phase 2 | withdrawn | Jan 9, 2026 | National Cancer Institute (NCI) | Study drug supplier withdrew support; no participants were enrolled. | Enrollment / accrual |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06939036 | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )(SANTANA-225) | Phase 1 / Phase 2 | terminated | Apr 22, 2025 | Ariceum Therapeutics GmbH | Study terminated due to strategic business decisions. | Sponsor / business decision |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Phase 1 / Phase 2 | terminated | Apr 3, 2019 | NeoImmuneTech | Strategic decision by sponsor | Sponsor / business decision |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen… | Phase 1 | withdrawn | Oct 23, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual | Enrollment / accrual |
| NCT03167164 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in… | Phase 1 / Phase 2 | withdrawn | May 25, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory… | Phase 2 | terminated | Nov 9, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | — | terminated | Dec 12, 2017 | Washington University School of Medicine | Subject recruitment was limited severely by the 2020-2023 COVID-19 pandemic, which led this study… | COVID-19 / pandemic |
| NCT03853317 | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma… | Phase 2 | terminated | Feb 25, 2019 | ImmunityBio, Inc. | Not meeting recruitment goal | Enrollment / accrual |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors… | Phase 1 / Phase 2 | terminated | Nov 13, 2019 | Turning Point Therapeutics, Inc. | Adverse change in the risk/benefit. | Safety / toxicity |
| NCT02465957 | QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) | Phase 2 | terminated | Jun 9, 2015 | ImmunityBio, Inc. | not stated | Not stated |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated…(AcceleRET-MTC) | Phase 3 | withdrawn | Feb 18, 2021 | Hoffmann-La Roche | Due to several logistical challenges during start-up which could not be overcome study was… | Other (stated, no rule matched) |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron… | Phase 2 | terminated | Aug 28, 2018 | University of Washington | Terminated due to low accrual. | Enrollment / accrual |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver… | Phase 2 | terminated | Jan 9, 2014 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT02036476 | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Jan 15, 2014 | Dana-Farber Cancer Institute | Lack of accrual. | Enrollment / accrual |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or… | Phase 1 / Phase 2 | terminated | Oct 19, 2020 | Xencor, Inc. | The study has been terminated early by the sponsor due to business decision. | Sponsor / business decision |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic… | N/A | terminated | Feb 16, 2015 | Icahn School of Medicine at Mount Sinai | No Current Funding | Funding |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT02584829 | Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without… | Phase 1 / Phase 2 | terminated | Oct 23, 2015 | Fred Hutchinson Cancer Center | Terminated due to loss in funding | Funding |
| NCT04874831 | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic… | Phase 2 | withdrawn | May 6, 2021 | 4SC AG | Refocusing of sponsor's clinical development program. No safety concern or change of the… | Safety / toxicity |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase 2 | withdrawn | Feb 12, 2019 | Antonio Fojo | Closed by sponsor | Other (stated, no rule matched) |
| NCT03988647 | Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Jun 17, 2019 | Stanford University | Business decision | Sponsor / business decision |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | Phase 2 | terminated | Feb 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual | Enrollment / accrual |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or… | Phase 2 | withdrawn | Sep 27, 2019 | M.D. Anderson Cancer Center | No Participants Registered | Other (stated, no rule matched) |
| NCT01913691 | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma | Phase 2 | withdrawn | Aug 1, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | Phase 2 | terminated | Dec 28, 2007 | University of Wisconsin, Madison | Budget/Funding | Funding |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome… | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual,primary endpoint reached \& investigator left NIH. | Investigator |
| NCT02054884 | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Feb 4, 2014 | Philogen S.p.A. | Lack of enrollment | Enrollment / accrual |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and… | Phase 1 | withdrawn | Jul 13, 2016 | Vanderbilt-Ingram Cancer Center | Loss of funding support | Funding |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Phase 2 | withdrawn | Apr 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT01758458 | Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma | Phase 1 / Phase 2 | terminated | Jan 1, 2013 | Fred Hutchinson Cancer Center | A Phase I/II study (NCT01758458) is now recruiting | Enrollment / accrual |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | Phase 2 | withdrawn | Sep 28, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | Phase 1 | terminated | Mar 26, 2004 | Yale University | not stated | Not stated |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic… | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 31, 2026source: clinicaltrials